Global Autogenous Vaccine for Aquaculture Market Size, Trends, and Analysis - Forecasts To 2026 By Fish Species (Salmon, Tilapia, Bream, Labris Bergylta, Cyprinus Carpio, Sea Bass, Trout, and Cylopterus Lumpus), By Pathogen (Bacteria and Virus), By End User (Aquatic Research Institute and Fish Farming Companies), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis
The global autogenous vaccine for the aquaculture market will register a descent growth between 2021-2026. The rising production of fish globally is increasing the demand for autogenous vaccines, to secure the fishes in the farms and stop the loss incurred by the disease outbreak in the fish ponds. According to the World Fish, the global fish market witnesses a loss of 6 billion USD every year, for these disease outbreaks in the fish ponds. The World Organization for Animal Health has set some strict protocols and guidelines to ensure the quality of fishes as well as to prevent these diseases from spreading.
Like all the other animals, the disease outbreaks also take place for the fishes in the fish farms or oceans. To ensure the growth of fish production and to maintain the secured quality of the fish it is very much needed to prevent those diseases from spreading with the help of proper autogenous vaccines. In developing countries, especially, the fish disease spreads rapidly as the aquaculture formed there is small scale and those firms do not hold enough investment for preventing the contamination. In different countries different guidelines, protocols, policies, and implementations about autogenous vaccinations are present.
However, with the expanding demand for fish and other seafood, the autogenous vaccine for the aquaculture market is getting more and more demand. Expanding commercialization of aquaculture in the developing countries, rising research and development for the invention of newer and advanced vaccines in the North American and European region, this market is expected to flourish globally in the forecasting period of 2021-2026.
Although in 2020 the market had faced some decline due to the pandemic emergency, the supply chains were harmed, many fish cultivation farms faced lockdown. Because of the short supply of vaccines and fewer numbers producers the market is currently not growing at a very high pace. To tackle this situation, many companies are taking steps toward producing vaccines on larger scales.
According to this fish species, the market is divided into several segments, Salmon, tilapia, bream, labris bergylta, cyprinus carpio, sea bass, trout, and cylopterus lumpus. However, Salmon and Tilapia are expected to secure the largest market share of autogenous vaccines for aquaculture mainly because these two species of fish are the most demanded ones in the fish market globally.
The increasing awareness about the nutritional value of Salmon is creating a great demand for this fish across the globe but these species tend to get more infected than the other fish species. Especially the countries like Brazil, Chilli, Mexico, Canada will experience high growth rates in this market for the segment of Salmon. The segment of tilapia also holds a high market share because of the same concern and it is also a very demanded fish. In the Nile region as well as the Asia Pacific region aquaculture of tilapia and commercialization of it is growing rapidly so to secure this fish species the demand for the autogenous vaccine for the same is growing with time.
According to the pathogen, an autogenous vaccine for the aquaculture market is divided into two segments, bacteria, and virus. However, bacteria, between these, accounts for more than 90% of the share in this market. It is expected to grow at the largest CAGR during the forecasting period mainly due to the easy approvals bacterial vaccines get in comparison to viral vaccines. Viral vaccines are also prohibited to use in many countries whereas bacterial vaccines are allowed in all the countries of the world. Other factors like the rising emergence of bacterial fish infections, rising implementation of policies, monitoring programs, and regulations by the governments in different countries are raising the demand for autogenous vaccines for aquaculture.
According to the end-users, the market is divided into two main segments, Aquatic Research Institute and Fish Farming company. Fish farming company is expected to account for the largest Market share during the forecasting period mainly due to the expanding sector of aquaculture and its wide commercialization of it.
With the growing population and the rising awareness programs about the nutritional value of aquatic animals and fishes, the aquaculture sector is growing rapidly. To ensure the quality and maintain the various government regulations and policies the demand for autogenesis vaccines in the aquaculture sector is increasing.
Geographically, China holds most of the aquaculture business in the world. The increasing awareness about zoonotic diseases and rising government investment for the health care of animals are contributing to the market for the autogenous vaccine for aquaculture to grow in the Asia-Pacific region at the largest rate of CAGR.
However, because of the increasing research and development and the rising investment for inventing new and advanced vaccines the region of North America is estimated to dominate the global autogenous vaccines market during the forecasting period. As per the United Nations Food and Agriculture Organization, only the fish farming industry of the US was valued at almost USD 400 million, in the year 2017. Mostly because of the increasing demand for fatty fisher and the changing consumption pattern from chicken and other animals to fish, is what drives the demand for more and more vaccines in this region.
IDT Biologika GmbH (Ridgeway Biologicals Ltd), Marinnovac (Aquatreck Animal Health S.L.), Ceva (Ceva Biovac), Zoetis (PHARMAQ AS), Vaxxinova, Barramundi Asia Pte Ltd.(UVAXX Asia), HIPRA, Virbac (ICTYO GROUP), AniCon Labor GmbH, Sanphar (IPEVE), AquaTactics Fish Health. Kennebec River Biosciences are some of the major vendors competing in the Autogenous Vaccine for Aquaculture market.
Please note: This is not an exhaustive list of companies profiled in the report.
In 2017, IDT Biologika GmbH collaborated with Gallant Custom Laboratories and launched a new firm in Canada to enhance their production quantitively.
In April 2018, Pharmaq announced that they are going to produce fish faction in a Chinese development center in Suzhou.
We value your investment and offer free customization with every report to fulfil your exact research needs.
The Global Autogenous Vaccine for Aquaculture Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Autogenous Vaccine for Aquaculture Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?